Data from the 18-patient study also showed enhanced benefits on PYY when the two drugs were dosed together

Patients in the study received ALKS 5461, a combination of an opioid modulator and buprenorphine, over a seven-day treatment period

The previous 12 patients in the study received stem cell transplants in the lumbar region of the spine, but patient 13 received the transplant in the gray matter of the cervical region

The 32-week, 841-patient study, designated Harmony 7, was designed to test albiglutide against once-daily GLP-1 Victoza in adults with Type II diabetes

Data from the 16-patient study were presented at the American Society of Nephrology's Kidney Week meeting in Philadelphia

The 400-patient study will be a noninferiority design with a primary endpoint of comparing fluid retention following treatment with ANX-514 administered without corticosteroid premedication, vs. Taxotere (docetaxel) administered with corticosteroid premedication

All patients in the study had chronic HCV genotype 1 infection and were new to treatment

The 42-patient study is comparing a low dose of Shigamabs vs

The firm previously completed enrollment in the 3,656-patient study and expects to report the primary safety analysis in the third quarter of 2012

The 83-patient study is designed to test APG101 plus reirradiation vs

Data from the 807-patient study, which measured the composite analysis of stool consistency and abdominal pain at week four compared with baseline symptoms, demonstrated that treatment with MuDelta was statistically superior to placebo, with patients treated at the 25-mg dose showing a 12 percent response rate, and patients treated at the 200-mg dose showing a 13.8 percent response, compared to a 5.7 percent response in the placebo group

Data from the 156-patient study previously showed a significant and dose-dependent reduction of both viral DNA and days with HSV lesions

Data from the randomized, open-label, 30-patient study are expected in mid 2012

The double-blind, placebo-controlled, NIH-funded, 297-patient study showed once-daily treatment for three days with 10-mg DAS181 resulted in a significant reduction of viral load when compared to placebo over the first 24 hours (p < 0.002), first 48 hours (p < 0.009) and from day one to day five (p < 0.008

Multiple patients in the study achieved stable disease, and one achieved partial response with 70 percent tumor regression

Allon Therapeutics Inc., of Vancouver, British Columbia, said data from an ongoing analysis of magnetic resonance imaging results from a 23-patient study showed that 12 weeks of treatment with neuroprotective candidate davunetide appeared to prevent cortical thinning of important parts of the brains of schizophrenia patients

The 190-patient study met its primary endpoint of reducing 28-day all-cause mortality, and the drug was shown to have an effect across a broad range of patients with different baseline characteristics

The double-blind, placebo-controlled, 1,600-patient study will have a primary endpoint of time-to-first-event composite event consisting of progression to end-stage renal disease, defined as the need for chronic dialysis or renal transplant, and cardiovascular death

Patients in the study ranged from 52 to 86 years